Leslie Chang Evertson, GNP Lead Dementia Care Manager · PDF fileNon-amnestic General function...
Transcript of Leslie Chang Evertson, GNP Lead Dementia Care Manager · PDF fileNon-amnestic General function...
Leslie Chang Evertson, GNP Lead Dementia Care Manager
UCLA Alzheimer’s and Dementia Care Program
1
DISCLOSURES
None of the faculty, planners, speakers, providers nor CME committee has any relevant financial relationships
with commercial interest There is no commercial support for this CME activity
2
Overview Prevalence What is dementia? Diagnosis Causes Management
3
Prevalence of Dementia Age Range % Affected 65-74 5% 75-84 15-25% 85 and older 36-50%
US: ~5.4 million with Alzheimer’s (2013) > 13 million by 2050 World wide: ~35 million with Alzheimer’s(2013) >115 million by 2050
4
Dementia Definition
DSM-IV Multiple cognitive deficits
Memory loss must be present One or more other deficit – aphasia (communication), apraxia
(motor execution), agnosia (recognition) , executive functions (synthesis)
Decline from prior level of function Deficits do not occur exclusively in the presence of
delirium DSM-V:
Memory loss not necessary Major Neurocognitive Disorder (NCD) vs. Minor NCD
5
DSM-V Definitions
Major neurocognitive disorder (major NCD or dementia) Minor neurocognitive disorder (minor NCD) Either can be further characterized by cause
Alzheimer’s disease FTD LBD Parkinson’s disease
Not Dementia - Delirium
Acute confusion or delirium in the setting of a medical illness Often occurs in the hospital Frequently caused by medications Usually resolves (days to weeks) Many cases are probably preventable Confusion Assessment Method (CAM)
7
Not Dementia - Depression Depression
Sad and withdrawn/anxiety Concentration impaired Memory complaints prominent Orientation intact Sometimes called “Pseudodementia” Geriatric Depression Scale or PHQ-9
8
Not Dementia - MCI Mild cognitive impairment Cognitive complaint Objective impairment in 1+ domains Amnestic Non-amnestic
General function intact 6-15% per year progress to dementia
Amnestic MCI Prominent memory complaint Objective memory loss (1.5 SD below age
norms); other cognition intact May be single or multiple domains
Non-amnestic MCI Primarily affects other domains (executive, language,
visual spatial) May be single or multiple domains May be less likely to progress to dementia
Not Dementia – Normal aging
Patient more concerned than family Can describe details of forgetfulness Intact recent memory for important events Word finding difficulties Function preserved
Diagnosing Dementia Screening (raises suspicion) 3 item recall Mini-Cog (3 item recall plus clock drawing) GPCOG (GP Assessment of Cognition) MIS (Memory Impairment Screen) MMSE, MOCA, and others
Screening tests identify more than 90% with dementia but do not establish a diagnosis
13
Diagnosing Dementia Clinician’s examination (usually PCP or Neurologist)
Mental Status Examination Physical Examination Psychosocial Examination Caregiver/Collateral input
Neuropsychological testing Lab and imaging tests to exclude medical conditions that
might be contributing Imaging: Structural MRI and/or Functional PET scan Labs: CBC, CMP, TSH, Vitamin B12
RPR & HIV if risk factors are present
14
Neuroimaging
Most useful if: Age of onset< 60 year Focal neuro deficits Abrupt onset or rapid decline Predisposing conditions (e.g. cancer, anticoagulation)
AAN: either CT or MRI PET: approved to distinguish AD from FTD Amyloid PET scans: for research purposes only
Causes of Dementia Alzheimer’s Disease 60-80% Vascular dementia 10-20% Dementia with Lewy bodies 15% Frontotemporal dementia 5% Toxic-metabolic disorders 4% Other movement disorders 6%
Dementia Risk Factors Factors that increase risk
Age -CV Risk factors Family history -Head trauma APOE-E4 -CKD Depression
Factors that reduce risk (variable evidence) APOE-E2 Mediterranean-type diet (fruits, veggies, fish) Higher physical activity/exercise Mental activity
Alzheimer’s Disease-Clinical Memory Language Visual-spatial Higher level (executive) Apathy
Alzheimer’s Disease: 2011 3 stages
Preclinical: defined by changes in biomarkers MCI: biomarkers may help determine progression to
AD Alzheimer’s Disease: biomarkers may be helpful in
excluding AD as cause
Framework for Biomarkers Measures Related to Molecular Pathology of Abeta
CSF Aβ42
Amyloid Imaging – PiB, AV-45
Measures Related to Neuronal Injury CSF tau/phopho tau MRI measures structural change
Hippocampal Volume Medial Temporal Lobe Atrophy
PET or SPECT measures of functional change FDG PET – temporoparietal topographic pattern SPECT Perfusion – temporoparietal topographic pattern
20
Diagnosing Dementia - Imaging
Amyloid PET Scan Imaging
21
Natural History and Complications Progression of cognitive decline
3-4 points on MMSE/year Non-cognitive symptoms
Psychotic symptoms (20%) Depressive symptoms (40%) Agitation or aggression (80%)
AD survival after symptom onset 3-12 yrs; other dementias have worse survival
Clinical Characteristics of FTD Personality changes Executive dysfunction
Social disinhibition Behavioral impulsivity
Hyperorality Pick’s disease:
a rapidly-progressive form of FTD Pick’s bodies (balloon-like intracellular inclusions)
can be seen on autopsy
FTD versus AD Gradual but faster onset than AD Younger age of onset than AD
Age of onset < 60 years usually Memory and gait impairment later and not as
pronounced as with AD Relative preservation of visual-spatial skills
Clinical Characteristics of LBD Core features:
Visual hallucinations (VH) Parkinsonian signs Fluctuating alertness and attention
Suggestive features: REM sleep disorder Sensitivity to antipsychotic medications and extrapyramidal side
effects (EPS) Supportive features:
Frequent falls Syncope Autonomic dysfunction Delusions
LBD Versus Other Dementias LBD versus AD
Motor deficits are more prominent in LBD early in the course Memory deficits are more prominent in AD
LBD versus dementia associated with Parkinson’s disease (PD) Motor and memory deficits tend to arise together within a year in
LBD Motor deficits arise first in PD; memory impairment is a later
finding
Clinical Characteristics of Vascular Dementia
Abrupt onset (may not be present) Stepwise deterioration (may not be present) Cognitive symptoms and motor signs correlate with
ischemia on neuroimaging Prominent aphasia is common Patients tend to have CVA risk factors
Mild Dementia (MMSE 21-25) Functional impairments • Managing finances
• Driving • Managing medications
Cognitive changes • Decreased insight • Short term memory deficits • Poor judgment
Behavioral issues • Social withdrawal • Mood changes: apathy/depression
Complications • Poor financial decisions • AEs due to medication errors
Moderate Dementia (MMSE 11-20) Functional impairments • IADL
• Difficulty with some ADLs • Gait and balance
Cognitive changes • Disoriented to date and place • Worse memory • Getting lost in familiar areas • Repeating questions
Behavioral issues • Delusions/ Agitation/Aggression • Apathy/depression • Restlessness/anxiety/wandering
Complications • Inability to remain at home/ALF • Falls
Severe Dementia (MMSE 0-10) Functional impairments • ADLs including continence
• Mobility • Swallowing
Cognitive changes • Little or unintelligible verbal output • Loss of remote memory • Inability to recognize family/friends
Behavioral issues • Motor or verbal agitation/aggression • Apathy/depression • Sundowning
Complications • Pressure sores • Contractures • Aspiration/pneumonia
Alzheimer’s Disease: A Two-Phase Strategy
31
Management Manage the disease
Cholinesterase inhibitors Memantine Vitamin E
Manage the patient Manage co-morbidities Caregiver support Behavioral therapies Drug management of complications Advanced planning
Manage the Disease Cholinesterase inhibitors
Donepezil (Aricept), galantamine (Razadyne) rivastigmine (Exelon)
May benefit Alzheimer’s Disease, LBD, Vascular (if also Alzheimer’s), and PD dementia
Do not benefit FTD Do not prevent progression of MCI to dementia
Effectiveness of Cholinesterase Inhibitors
Most often drug slows progression 10-25% of patients improve Behavioral symptoms may improve Some decline rapidly when drug discontinued
Memantine Memantine (Namenda) Slows rate of functional and cognitive decline and
improves behavioral symptoms FDA indication for moderate-severe AD Not effective in mild-moderate disease
Memantine plus Cholinesterase Inhibitor
Early studies showed better outcomes (cognition, activities of daily living, global outcome, and behavior) than cholinesterase inhibitor alone in moderate to severe dementia
But more recent studies have cast doubt on whether the combination is more effective
Vitamin E Mixed results in trials TEAM-AD VA Cooperative Trial
Mild-to-moderate dementia (MMSE 12-26) 4 arms (Vit E 2000 IU, memantine, both, none) Vit E slower rate of decline (19% per year) No benefit from memantine 42% did not complete the study
Jama 2014; 311:33-44.
Not Beneficial Vitamin B6, B12, or folate Gingko biloba Hormones (testosterone, estrogen) Statins Aspirin or other NSAIDs Vaccines Anti-amyloid treatment
Manage the Patient This is a lifelong disease Play the ball where it lies
If disease is early, include patient If late, rely on family and caregiver
Aim for the highest level of independence that works for everyone
Manage hot-button issues (e.g., driving) Manage other diseases Manage symptoms
Caregiver Support Caregivers are the most important resource a
demented patient has Over 50% develop depression The more knowledgeable and more empowered the
caregiver is, the better care the patient will receive Caregiver resources are available
Alzheimer’s Association and other community resources Counseling, Support Groups Respite – Hiring a help, Adult Day, placement
Management of behavioral and psychological complications
With medications:
Antidepressants Citalopram 30 mg for agitation
Reduced agitation Worsened MMSE scores Increased QTc
JAMA 2014;311:682-91
Management of behavioral and psychological complications
Antipsychotics (e.g., risperadone, quetiapine, olanzapine) Not very effective Have potential for side effects Some patients benefit
Mood stabilizing medications (e.g., valproate) Dextromethorphan/quinidine
JAMA 2015 Sep 22-29;314(12):1242-54
Behavioral Modifications
Reorient – Explain to the patient where he or she is and why he or she is there. Be sure to introduce yourself and speak in a confident yet reassuring tone. It is not always important to remind or correct the patient of the date, your specific title, etc.
Behavioral Modifications
Redirect – Divert attention by asking an unrelated question, ask the patient to help you with an activity or offer to take the patient for a walk.
Behavioral Modifications
Identify triggers – Did the patient become agitated during a bath? Medication? When he is in pain? Male or female caregivers? Daytime or nighttime? Family members?
Behavioral Modifications
Create a calm environment – This is difficult to do in a hospital setting. Perhaps the patient shares a room with another patient who has a lot of visitors or doctors; this can be anxiety producing. Avoid loud television, harsh lights, alarms, etc.
Behavioral Modifications
Offer a guess – Patients with dementia often cannot tell you what is bothering them. If they cannot find a word, offer some limited suggestions, don’t try to correct them. Try to avoid arguing with them.
Behavioral Modifications
Supervise – For some patients, memory impairment may be so severe, none of these interventions last but a minute or two. For these patients, sitters should be employed if possible before using sedation medications. http://www.alz.org http://dementia.uclahealth.org/body.cfm?id=68
And more to consider… Non-pharmacological behavioral modifications Caregiver stress and strain Financial resources Legal concerns Insurance coverage (Private insurance, Medicare, Medi-Cal, LTCi) Private caregiving Adult Day Care Support groups Assisted Livings Nursing Homes Unbefriended Elder abuse
49
Conclusions Dementia is an epidemic, particularly among the oldest old Many diseases have symptoms of dementia but are not
dementia History taking and mental status exam are still critical
elements of diagnosis Diagnostic testing is generally confirmatory but occasionally
some surprises
Conclusions Providers can do much more for dementia patients now than a
decade ago Drugs to prevent disease progression and treat complications
are still limited Behavioral management and caregiver support are essential Potential new therapies are a long way off
Helpful Websites Alzheimer’s Association http://www.alz.org/ Lewy Body Dementia Association https://www.lbda.org/ The Association for Frontotemporal Degeneration
http://www.theaftd.org/ AIDS.gov https://www.aids.gov/hiv-aids-basics/staying-healthy-with-
hiv-aids/potential-related-health-problems/dementia/ National Institute of Neurological Disorders and Stroke
http://www.ninds.nih.gov/disorders/disorder_index.htm#V CDC – STD Treatment Guidelines
http://www.cdc.gov/std/tg2015/syphilis.htm UCLA Alzheimer’s and Dementia Care Program
http://dementia.uclahealth.org/
52
Thank you Leslie Chang Evertson, GNP Lead Dementia Care Manager UCLA Alzheimer’s and Dementia Care Program 200 UCLA Medical Plaza Suite 365A Los Angeles, CA 90095 Phone: (310)319-3222 [email protected] http://dementia.uclahealth.org
53